Dr. Clay Siegall is known to many because of his numerous accomplishments in the biotechnology world. At the moment, the respected scientist is the chief executive officer for one of the most successful biotechnology companies in the United States, known as Seattle Genetics. The scientist is also the chairman of the board of directors. As the leader of the institution, Clay Siegall has done a lot to make sure that the company develops drugs that help the individuals living with cancer.
Cancer has become very popular in the world at the moment. There are different types of cancers that affect different parts of the body. Many physicians and researchers have spent a lot of time researching the best cure for the disease, but most of them have not been successful. It is evident that people are dying every day due to lack of proper medication. Individuals like Clay Siegall, however, are giving hope to cancer patients.
Clay went to study zoology at one of the most prestigious universities in the world, known as George Washington University. The institution is based in the US, and it has impacted the lives of many people. After acquiring his first degree, the businessman realized that there was no good cure for cancer. Clay watched when his father was diagnosed with the dangerous disease several years ago. According to him, the type of medicine that was used to treat him only made the situation worse, and this motivated him to look for a better and more reliable cure for the condition. This realization forced him to join the George Washington University for a PhD in genetics. The skills he acquired at the school have played a fundamental role in his successful career.
The businessman decided to start Seattle Genetics several years ago to help the individuals living with the dangerous disease. The first drug from the company has already hit the market, and it has already been accepted in more than sixty nations. The drug is known as ADCEATRIS, and it has changed the lives of many cancer patients. Clay Siegall says that his company will soon be introducing more drugs to treat several types of cancer. The company will also be increasing its employees to cater to the growing need of cancer treatment. Breast cancer is one of the cancers the institution wishes to address in the recent future. According to the company management, this is one of the most common cancers.
Just by considering the laudable accomplishments of the company Clay Siegall leads, one should be able to have a glimpse of the admirable qualities of this noble personality. Clay Siegall doubles as Co-Founder and CEO of Seattle Genetics. Since 1998 when the company came on board, it has been making redoubtable inroads in cancer research. The company has brought massive innovations and advancements in cancer therapy with its stock price tripling within the space of 5 years.
Under the watch of Siegall, Settle Genetics has severally commanded the attention of the world with ground-breaking therapies for cancer patients. For instance, the company was the first to come up with antibody-drug conjugates (ADCs). ADCETRIS® (brentuximab vedotin) was the first of its kind and an invention of Settle Genetics under the leadership of Siegall. Today over 60 countries round the globe are making use of ADCETRIS® in treating cancer patients with amazing testimonies of its effectiveness.
Few individuals can rival Siegall, particularly, in the area of visionary leadership. Many people already know him for his in-depth scientific acumen. The combination of these two amazing qualities has left staff of Seattle Genetics wondering if they can ever have a better leader. He spare-headed the fund-raising of over $1.2 billion for the company. Little wonder Settle Genetics keeps paving the way in innovative technologies necessary for discovering better treatment options for cancer.
Siegall’s commitment and passion towards the complete eradication of cancer leaves people wondering if he will ever show signs of weariness. He seems not to be contented with the 15 patents he currently holds. There are several publications to his credit on new research methods and discoveries. He is currently in the editorial board of three notable scientific journals with over 70 scientific articles in his name.
With such significant contributions to the medical well-being of the human race, it is no surprise catalogue of awards keep coming in and obviously more are on way. University of Maryland where he obtained his PhD in Genetics conferred on him the institution’s award for the Alumnus of the Year for Computer, Math and Natural Science in 2013. A year before then, he was named the Pacific Northwest Ernst & Young Entrepreneur of the Year.
Indeed, Clay Siegall remains a formidable force for wining the war against cancer and other related diseases.